A global regulatory organization may appear structurally robust on paper yet perform inconsistently in practice. Excessive centralization can weaken sensitivity to jurisdiction-specific regulatory expectations, authority precedents, procedural requirements, and local implementation realities. Conversely, excessive decentralization can fragment regulatory governance, resulting in duplicated activities, inconsistent dossier positions, conflicting commitments, and divergence in the interpretation of the same scientific and regulatory evidence. There is no universally prescribed organizational model for pharmaceutical regulatory affairs.
The most effective structure depends on the complexity of the product portfolio, stage of development, geographic scope, regulatory pathway, operating model, outsourcing strategy, and the degree of coordination required across global, regional, and local markets. The value of this model does not come from adding more management levels, it comes from assigning the right decision rights, accountability and regulatory knowledge to each layer. That distinction is increasingly important as global regulatory strategy, regulatory data standards, eCTD v4.0, Regulatory Information Management (RIM), regulatory intelligence and AI change how regulatory work is distributed across organizations.
Why Global Regulatory Teams Cannot Operate as One Centralized Function
One global team can create common standards, reduce duplication, maintain global product knowledge and establish consistent regulatory positions, but pharmaceutical regulation remains jurisdiction specific.
ICH harmonization, CTD standards and increasingly structured regulatory data have made global reuse easier, but they have not created one worldwide medicines regulator.
Even eCTD v4.0 combines a harmonized technical standard with regional Module 1 requirements. ICH explicitly states that its eCTD v4.0 implementation package must be used alongside regional requirements, and implementation continues according to national or regional procedures.
The global team should create the common regulatory direction. It should not attempt to replace market-specific regulatory judgment. The opposite model is equally problematic. The objective is therefore controlled decentralization. Global consistency where consistency creates value. Local authority ownership where local knowledge matters.
What Should Global Regulatory Affairs Own?
Global Regulatory Affairs should own decisions that need to remain consistent across the product lifecycle. Its role is strategic rather than simply administrative.
Global product regulatory strategy
Global should define the core global regulatory strategy covering:
- Target indications
- Development pathway
- Major authority engagement strategy
- Pivotal evidence package
- Global filing principles
- Key regulatory risks
- Major CMC positions
- Global benefit-risk narrative
- Sequencing principles
- Major post-approval strategy
What regulatory position is the company trying to defend across markets?
Regional and local teams can adapt execution, but they should not unknowingly create competing scientific positions.
Global core dossier governance
Global Regulatory Affairs should govern the scientific core from which regional and local submissions are developed.
That includes alignment across:
- Modules 2–5
- Core clinical evidence
- Core CMC information
- Nonclinical information
- Global responses to major scientific questions
- Core labeling positions where applicable
The goal is not to make every submission identical; it is to make every regulatory difference intentional and traceable.
Major health-authority strategy
Global teams should generally coordinate interactions that can materially affect the wider development or lifecycle strategy.
For example:
- Major scientific advice
- Pivotal development discussions
- Global safety positions
- Major CMC questions
- Significant changes to indication strategy
- Cross-market commitments
Local specialists may participate or lead authority interaction depending on the jurisdiction, but the strategic implications should remain globally visible.
Cross-market risk decisions
If an authority request in one country could affect ten other markets, it is no longer only a local issue.
Global Regulatory Affairs should maintain escalation mechanisms for:
- Significant authority objections
- Emerging safety issues
- Critical CMC changes
- Major labeling divergence
- New clinical requirements
- Commitments likely to affect other markets
Global ownership therefore means portfolio consistency, not global control of every submission.
What Should Regional Regulatory Teams Own?
Regional teams sit between global product strategy and individual country execution. Their value is greatest where multiple countries share regulatory frameworks, procedures, standards or strategic similarities.
A regional role may cover areas such as:
- European Union
- Asia-Pacific
- Latin America
- Middle East and Africa
- Other company-defined geographic clusters
Translate global strategy into regional pathways
Regional teams should identify how the global regulatory position translates into the relevant regulatory environment.
This may involve:
- Regional authorization pathways
- Region-specific submission expectations
- Common labeling requirements
- Regional reliance opportunities
- Procedural sequencing
- Regional CMC considerations
- Pharmacovigilance solutions requirements
- Post Approval lifecycle Management
For example, EU regulatory strategy involves pathways and procedures that cannot simply be inferred from US strategy. Depending on the product and circumstances, EU authorization may involve centralized, decentralized, mutual-recognition or national routes.
Coordinate related markets
Regional teams can prevent individual affiliates from solving the same problem repeatedly.
If ten markets have similar requirements, the regional team can:
- Establish a common interpretation
- Coordinate the evidence package
- Identify reusable responses
- Align timing
- Escalate genuine exceptions
This is particularly valuable where one authority decision or reference-market position affects several downstream markets.
Consolidate regional intelligence
Regional teams should turn country-level observations into patterns.
What Should Local Regulatory Affairs Own?
Local Regulatory Affairs should own what cannot be reliably managed from headquarters.
The local function is closest to:
- National legislation
- Authority procedures
- Local submission practices
- Current regulator expectations
- Local administrative requirements
- Authority communication
- Local product lifecycle obligations
Local regulatory interpretation
- A global team may understand the product better.
- The local team may understand the regulator better.
- Both forms of expertise matter.
- Local Regulatory Affairs consultant should determine how global strategy applies under the actual rules and operating environment of the market.
Submission execution
Local responsibility commonly includes:
- Country-specific forms
- Module 1 requirements
- Local administrative documents
- Translation requirements
- Local portal/process requirements
- Fees and procedural steps
- National labeling adaptations
- Authority questions
- Market-specific lifecycle submissions
The exact activities vary significantly by jurisdiction.
Authority relationship and intelligence
Local regulatory professionals often identify changes before those changes become obvious at global level.
That may include:
- Evolving authority expectations
- Procedural bottlenecks
- Interpretation changes
- New local guidance
- Informal but important submission practices
- Emerging regulatory precedents
The role of local Regulatory Affairs is therefore not simply “submit what global sends”, a strong local team is an intelligence node within the global regulatory network.
Global vs regional vs Local: Who Should Make the Final Decision?
This is where many regulatory operating models fail, they define responsibilities but not decision rights.
Consider a situation where:
- Global wants one indication
- Regional believes the pathway creates risk
- Local Regulatory Affairs believes the authority will reject the proposed position.
Regulatory Operations and RIM are Changing the Organizational Model
Modern regulatory operations increasingly manage relationships between:
Product → Substance → Manufacturer → Market → Application → Submission → Approval → Commitment → Variation → Lifecycle Event
This shift matters because regulatory information is becoming more structured and reusable.
EMA’s SPOR framework, for example, is implementing ISO IDMP through standardized substance, product, organization and referential master data. EMA describes these master-data services as foundations for regulatory processes and product information management.
EMA’s 2026–2028 planning also emphasizes high-quality regulatory master data and continued development of the Product Management Service as part of a broader regulatory data foundation.
eCTD v4.0 adds another layer. The latest ICH Implementation Guide, version 1.7, was endorsed in June 2026 and supports a more metadata-driven submission environment while still retaining regional implementation requirements, this changes the role of Regulatory Operations.
The function increasingly needs capabilities in:
- Submission standards
- Regulatory data governance
- Metadata
- RIM
- Document lifecycle
- Submission publishing
- Data quality
- Controlled vocabularies
- Product-registration data
- Technology governance
Regulatory Operations should therefore not sit at the end of the process as the team that “publishes the dossier”, it should be part of the regulatory operating model from the beginning.
RIM creates shared visibility
A good RIM environment can allow global, regional and local teams to work from the same regulatory record while maintaining different responsibilities.
Regulatory Roles Should Not Be Designed in Isolation
Regulatory Affairs cannot be structured properly without looking at the functions around it.
- A submission strategy depends on Clinical.
- A manufacturing change depends on Quality and CMC.
- A safety position depends on Pharmacovigilance.
- A label depends on Medical, Safety, Commercial and Regulatory considerations.
- A launch depends on Supply Chain and market readiness.
Regulatory + Clinical
Clarify who owns:
- Authority feedback affecting clinical development
- Protocol-related regulatory strategy
- Regional clinical evidence questions
- Commitments arising from approval
Regulatory + CMC/Quality
Clarify who owns:
- CMC regulatory strategy
- Health-authority questions
- Change assessment
- Post-approval variation classification
- Implementation approval status
Regulatory + Pharmacovigilance
Clarify ownership across:
- RMPs
- Safety variations
- Labeling changes
- Signal-related authority communication
- Post-authorisation measures
Regulatory + Supply Chain
Clarify when product can legally be:
- Manufactured under changed conditions
- Released
- Packaged
- Imported
- Distributed in each market
How AI and Regulatory Intelligence are Changing Regulatory Roles in 2026
AI is not removing the need for regulatory professionals; it is changing where human regulatory judgment creates the most value.
In January 2026, US-FDA and EMA jointly published ten guiding principles for good AI practice in drug development. They emphasize, among other things, human-centric design, risk-based use, multidisciplinary expertise, data governance, lifecycle management and clear context of use.
EMA’s current data and AI strategy also reflects a broader move toward using AI and large regulatory datasets to support analysis, productivity and regulatory decision-making. Its 2026–2028 Network Data Steering Group workplan includes data standardization, AI guidance, Product Management Service development and increased use of regulatory and health data. Regulatory intelligence becomes more continuous
AI-assisted systems can increasingly help teams:
- Monitor regulatory sources
- Classify developments
- Compare requirements
- Identify potentially affected products
- Summarize changes
- Prioritize human review
Global teams gain broader visibility
AI-enabled regulatory intelligence can help global teams identify patterns across authorities and markets faster, but it should not eliminate local validation. A generated interpretation of a national regulatory requirement is not equivalent to a validated local regulatory position.
Local teams become validators and context owners
As automated systems make global information easier to access, local Regulatory Affairs becomes more—not less—important for high-value interpretation.
The local role shifts from being an information gateway toward being the owner of:
- Contextual interpretation
- Authority nuance
- Precedent validation
- Implementation reality
Regulatory Operations becomes more data-oriented
As AI systems depend on reliable regulatory data, poor RIM quality becomes a bigger organizational problem. AI does not repair ambiguous ownership, incomplete product records or inconsistent regulatory classifications automatically. Strong data governance becomes a prerequisite.
A Practical Global Regulatory Operating Model for Pharma Companies
Instead of building the organization around geography alone, pharma companies can structure regulatory responsibilities around five layers of work.
Layer 1 — Enterprise regulatory governance
Primary owner: Global Regulatory Affairs
Own:
- Global standards
- Governance
- Regulatory policy
- Strategic escalation
- Enterprise risk
- Major authority strategy
Layer 2 — Product regulatory strategy
Primary owner: Global Product Regulatory Lead
Own:
- Product regulatory strategy
- Global dossier position
- Development pathway
- Cross-market evidence strategy
- Major lifecycle decisions
Layer 3 — Regional translation
Primary owner: Regional Regulatory Lead
Own:
- Regional pathways
- Market clustering
- Regional regulatory intelligence
- Regional alignment
- Coordination of related submissions
Layer 4 — Local execution and authority ownership
Primary owner: Local Regulatory Affairs
Own:
- local requirements
- authority interface
- national submission execution
- local lifecycle procedures
- local intelligence
- escalation of market-specific risks
Layer 5 — Regulatory infrastructure
Primary owner: Regulatory Operations / RIM
Own:
- Regulatory systems
- Submission operations
- Registration data
- Dossier Submission/Document lifecycle
- Metadata
- Data quality
- Dashboards
- Regulatory records
Conclusion
The best global regulatory organization is neither completely centralized nor completely local, it distributes decision-making according to regulatory impact.
Global Regulatory Affairs should protect the scientific and strategic consistency of the product. Regional teams should translate that strategy across related regulatory environments. Local Regulatory Affairs should own the market-specific interpretation, authority relationship and execution that cannot be managed reliably from headquarters.
Regulatory operations and RIM should connect those layers through accurate regulatory data, controlled submission processes and shared lifecycle visibility. AI and regulatory intelligence will make information easier to discover and analyse, but they make accountability more important—not less. For global pharma companies, the goal should therefore be a regulatory organization where strategy is global, coordination is regional, execution is local, and regulatory information is shared.
DDReg supports pharmaceutical companies across global regulatory strategy, market-specific regulatory execution, lifecycle management and technology-enabled regulatory operations. It’s regulatory strategy services included global registration strategy, lifecycle management, technical advisory and regulatory communication across markets. The strongest regulatory operating model is not the one with the most centralized control. It is the one that puts each regulatory decision in the hands of the team best equipped to make it—without losing global visibility.
Frequently Asked Questions
Regional teams connect global strategy with groups of markets that share regulatory frameworks, procedures or strategic characteristics. They can coordinate related submissions, consolidate regional intelligence and prevent unnecessary duplication across local affiliates.
Regulatory Operations should operate across global, regional and local Regulatory Affairs rather than functioning only as an end-stage publishing team. Its role increasingly includes RIM, regulatory data governance, submission standards, metadata, document lifecycle and portfolio visibility.
AI can accelerate regulatory intelligence monitoring, document analysis, information classification and pattern identification. Human regulatory professionals remain responsible for context, scientific interpretation, risk assessment and accountable decision-making. FDA and EMA's 2026 Good AI Practice principles emphasize human-centric, risk-based and multidisciplinary use of AI.
RIM provides the shared product, market, submission, approval and lifecycle data needed to execute a global regulatory strategy consistently. Without reliable regulatory information, global and local teams can make decisions from conflicting versions of the regulatory record.